Trial Profile
A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical
- 31 Aug 2020 Status changed from active, no longer recruiting to completed.
- 19 Mar 2020 Planned number of patients changed from 40 to 50.
- 19 Mar 2020 Status changed from recruiting to active, no longer recruiting.